retatrutide expanded access program White House officials on Tuesday shot down a report speculating that President Trump gained to the weight-loss drug under the Food and Drug Administration's (FDA) “compassionate use program.” Read more Lilly's Retatrutide expanded access program
Description
Sjolund et al., 1983)
Central and peripheral GLP1 systems independently suppress eating
Colloquially, these changes are referred to on social media as semaglutide face or Ozempic face, based on the commercial names of semaglutide
This format allows for predictable absorption and long-acting appetite regulation, making it suitable for patients requiring stable, sustained GLP-1 exposure
Although side effects are often less intense than with standard dosing, patients may still experience nausea, diarrhea, or fatigue
Q Do you have any closing thoughts
